HK1223036A1 - 含有吡啶基氨基乙酸化合物的药物制剂 - Google Patents

含有吡啶基氨基乙酸化合物的药物制剂 Download PDF

Info

Publication number
HK1223036A1
HK1223036A1 HK16111395.0A HK16111395A HK1223036A1 HK 1223036 A1 HK1223036 A1 HK 1223036A1 HK 16111395 A HK16111395 A HK 16111395A HK 1223036 A1 HK1223036 A1 HK 1223036A1
Authority
HK
Hong Kong
Prior art keywords
pyridin
salt
pharmaceutical preparation
pyrazol
acetate
Prior art date
Application number
HK16111395.0A
Other languages
English (en)
Chinese (zh)
Inventor
‧沙姆斯
N‧沙姆斯
‧克朗
H-A‧克朗
川田久
川端敬子
Original Assignee
参天制药株式会社
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53520400&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1223036(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 参天制药株式会社 filed Critical 参天制药株式会社
Publication of HK1223036A1 publication Critical patent/HK1223036A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK16111395.0A 2014-01-10 2015-01-08 含有吡啶基氨基乙酸化合物的药物制剂 HK1223036A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461925882P 2014-01-10 2014-01-10
US61/925,882 2014-01-10
PCT/JP2015/050366 WO2015105144A1 (ja) 2014-01-10 2015-01-08 ピリジルアミノ酢酸化合物を含む医薬製剤

Publications (1)

Publication Number Publication Date
HK1223036A1 true HK1223036A1 (zh) 2017-07-21

Family

ID=53520400

Family Applications (1)

Application Number Title Priority Date Filing Date
HK16111395.0A HK1223036A1 (zh) 2014-01-10 2015-01-08 含有吡啶基氨基乙酸化合物的药物制剂

Country Status (26)

Country Link
US (9) US9415038B2 (enExample)
EP (3) EP3424503B1 (enExample)
JP (7) JP5846338B2 (enExample)
KR (1) KR101824829B1 (enExample)
CN (2) CN108743587B (enExample)
AU (1) AU2015205188B2 (enExample)
BR (1) BR112016015763B8 (enExample)
CA (1) CA2936026C (enExample)
CL (1) CL2016001756A1 (enExample)
DK (1) DK3093018T3 (enExample)
EA (1) EA031734B1 (enExample)
ES (2) ES2711091T3 (enExample)
GE (1) GEP20186917B (enExample)
HK (1) HK1223036A1 (enExample)
HU (1) HUE041653T2 (enExample)
IL (1) IL246447B (enExample)
MX (1) MX370361B (enExample)
MY (1) MY163235A (enExample)
PH (1) PH12016501357B1 (enExample)
PL (1) PL3093018T3 (enExample)
PT (1) PT3093018T (enExample)
SG (1) SG11201605653RA (enExample)
TR (1) TR201902019T4 (enExample)
TW (1) TWI598113B (enExample)
UA (1) UA117506C2 (enExample)
WO (1) WO2015105144A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3093018T (pt) 2014-01-10 2019-01-10 Santen Pharmaceutical Co Ltd Preparação farmacêutica incluindo um composto de ácido piridilaminoacético
CA2935055C (en) 2014-01-10 2021-08-24 Santen Pharmaceutical Co., Ltd. Pharmaceutical composition containing pyridylaminoacetic acid compound
GEP20186916B (en) * 2014-01-10 2018-11-12 Pharmaceutical Co Ltd Santen Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition
MX2017007572A (es) * 2014-12-12 2018-02-09 Kowa Co Composicion acuosa.
RU2749952C2 (ru) * 2015-07-01 2021-06-21 Сантэн Фармасьютикал Ко., Лтд. Депо-препарат, содержащий сложный эфир лимонной кислоты
EP3320904B1 (en) * 2015-07-09 2023-07-05 Santen Pharmaceutical Co., Ltd. Preventative and/or therapeutic agent containing pyridyl aminoacetic acid compound for treating a disease involving a greatly elevated intraocular pressure
US20200121652A1 (en) 2017-06-16 2020-04-23 The Doshisha Compounds having caspase inhibitory activity, pharmaceutical agent containing said compounds and for treating or preventing corneal endothelial symptoms, disorders, or diseases, and application of said pharmaceutical agent
EP3639854A4 (en) 2017-06-16 2021-03-03 The Doshisha MTOR INHIBITIVE MEDICINAL PRODUCT FOR THE TREATMENT OR PREVENTION OF OPHTHALMIC SYMPTOMS, DISORDERS, OR DISEASES AND USE THEREOF
EP3689349A4 (en) * 2017-09-29 2021-06-23 Santen Pharmaceutical Co., Ltd. MEDICINAL PRODUCT CONTAINING A COMPOUND OF PYRIDYLAMINOACETIC ACID
CA3086445A1 (en) 2017-12-21 2019-06-27 Santen Pharmaceutical Co., Ltd. Omidenepag combination
WO2019131901A1 (ja) * 2017-12-28 2019-07-04 参天製薬株式会社 ピリジルアミノ酢酸化合物を含有する医薬製剤
BR112020021845A2 (pt) * 2018-04-24 2021-02-23 Allergan, Inc. tratamentos para presbiopia

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002356420A (ja) * 2001-03-27 2002-12-13 Santen Pharmaceut Co Ltd 安定な水性液剤
DK2264009T3 (en) * 2008-03-12 2019-04-15 Ube Industries PYRIDYLAMINE ACEDIC ACID COMPOUND
PL2415763T3 (pl) 2009-03-30 2016-05-31 Ube Industries Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry
JP2011057633A (ja) * 2009-09-11 2011-03-24 Ube Industries Ltd ピリジルアミノ酢酸化合物を含有する医薬
US20120202863A1 (en) * 2011-02-03 2012-08-09 Gerald Horn Compositions and methods for treatment of glaucoma
US9339496B2 (en) 2012-07-13 2016-05-17 Santen Pharmaceutical Co., Ltd. Composition for treating or preventing glaucoma comprising a sulfonamide compound, and a beta-receptor antagonist
US20140018350A1 (en) 2012-07-13 2014-01-16 Asahi Glass Co., Ltd. Combination of sulfonamide compound and tafluprost
JP6193655B2 (ja) * 2012-07-13 2017-09-06 参天製薬株式会社 スルホンアミド化合物の組み合わせ
JP2014019650A (ja) * 2012-07-13 2014-02-03 Santen Pharmaceut Co Ltd スルホンアミド化合物とタフルプロストの組み合わせ
PT3093018T (pt) * 2014-01-10 2019-01-10 Santen Pharmaceutical Co Ltd Preparação farmacêutica incluindo um composto de ácido piridilaminoacético
CA2935055C (en) * 2014-01-10 2021-08-24 Santen Pharmaceutical Co., Ltd. Pharmaceutical composition containing pyridylaminoacetic acid compound
GEP20186916B (en) 2014-01-10 2018-11-12 Pharmaceutical Co Ltd Santen Pyridylaminoacetic acid compound and polyoxyethylene castor oil-containing pharmaceutical composition

Also Published As

Publication number Publication date
CN105899209B (zh) 2018-09-11
EA201691402A1 (ru) 2016-10-31
JP7402922B2 (ja) 2023-12-21
PT3093018T (pt) 2019-01-10
CA2936026C (en) 2022-04-19
US10179127B2 (en) 2019-01-15
US10702511B2 (en) 2020-07-07
EP3093018A4 (en) 2017-09-13
USRE48183E1 (en) 2020-09-01
CL2016001756A1 (es) 2017-05-12
US20220054466A1 (en) 2022-02-24
TW201609186A (zh) 2016-03-16
JP2022111280A (ja) 2022-07-29
US9415038B2 (en) 2016-08-16
EP3093018A1 (en) 2016-11-16
US20200289483A1 (en) 2020-09-17
EP3093018B1 (en) 2018-11-28
CN105899209A (zh) 2016-08-24
BR112016015763B1 (pt) 2020-09-01
US11197849B2 (en) 2021-12-14
AU2015205188B2 (en) 2019-11-14
JP7087040B2 (ja) 2022-06-20
JP2025142352A (ja) 2025-09-30
JP7726542B2 (ja) 2025-08-20
CN108743587B (zh) 2021-04-30
AU2015205188A1 (en) 2016-07-14
UA117506C2 (uk) 2018-08-10
GEP20186917B (en) 2018-11-12
US20180169079A1 (en) 2018-06-21
US20160324838A1 (en) 2016-11-10
PL3093018T3 (pl) 2019-05-31
IL246447A0 (en) 2016-08-31
EA031734B1 (ru) 2019-02-28
EP3750541A1 (en) 2020-12-16
PH12016501357B1 (en) 2020-12-09
JP5846338B2 (ja) 2016-01-20
US20250235439A1 (en) 2025-07-24
KR20160101030A (ko) 2016-08-24
DK3093018T3 (en) 2019-02-04
MX370361B (es) 2019-12-10
NZ721620A (en) 2021-08-27
US11793798B2 (en) 2023-10-24
US12295946B2 (en) 2025-05-13
TR201902019T4 (tr) 2019-03-21
JP2021006593A (ja) 2021-01-21
EP3424503A1 (en) 2019-01-09
US20240000763A1 (en) 2024-01-04
US20190105310A1 (en) 2019-04-11
SG11201605653RA (en) 2016-08-30
MX2016009063A (es) 2016-09-28
US9943510B2 (en) 2018-04-17
PH12016501357A1 (en) 2016-08-15
CN108743587A (zh) 2018-11-06
JP2016027060A (ja) 2016-02-18
EP3424503B1 (en) 2020-09-02
JP6491588B2 (ja) 2019-03-27
HUE041653T2 (hu) 2019-05-28
WO2015105144A1 (ja) 2015-07-16
JP2019108363A (ja) 2019-07-04
JP2024019479A (ja) 2024-02-09
JP6785330B2 (ja) 2020-11-18
KR101824829B1 (ko) 2018-02-01
US20150196541A1 (en) 2015-07-16
IL246447B (en) 2020-06-30
ES2711091T3 (es) 2019-04-30
BR112016015763B8 (pt) 2020-09-15
JPWO2015105144A1 (ja) 2017-03-23
MY163235A (en) 2017-08-30
ES2834334T3 (es) 2021-06-17
CA2936026A1 (en) 2015-07-16
TWI598113B (zh) 2017-09-11

Similar Documents

Publication Publication Date Title
CN108743587B (zh) 含有吡啶基氨基乙酸化合物的药物制剂
JP2021095406A (ja) ピリジルアミノ酢酸化合物を含有する予防及び／又は治療剤
HK1225280A1 (en) Pharmaceutical preparation including pyridylamino acetic acid compound
HK1225280B (en) Pharmaceutical preparation including pyridylamino acetic acid compound